Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Privitera

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Journal of Crohn'S & Colitis|June 18, 2026
Virtual chromoendoscopy with linked color imaging versus dye-chromoendoscopy in the surveillance of patients with long-standing colonic inflammatory bowel diseaseRoberto Gabbiadini, Gianluca Franchellucci, Francesco Minini, et al.
Journal of Crohn'S & Colitis|December 27, 2025
Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC studyGiuseppe Privitera, Cristina Bezzio, Arianna Dal Buono, et al.
United European Gastroenterology Journal|November 9, 2019
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel diseaseLuisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, et al.
Neurogenetics|February 5, 2013
Natural history of neurofibromatosis type 2 with onset before the age of 1 yearMartino Ruggieri, Anna Lia Gabriele, Agata Polizzi, et al.
Cancers|February 5, 2021
Challenges in Crohn's Disease Management after Gastrointestinal Cancer DiagnosisClaudio Fiorillo, Carlo Alberto Schena, Giuseppe Quero, et al.
Expert Opinion on Biological Therapy|October 19, 2020
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patientsDaniela Pugliese, Luisa Guidi, Giuseppe Privitera, et al.
Journal of Crohn'S & Colitis|July 17, 2020
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel DiseaseGiuseppe Privitera, Sara Onali, Daniela Pugliese, et al.
La Radiologia Medica|October 19, 2016
Uveal melanoma: quantitative evaluation of diffusion-weighted MR imaging in the response assessment after proton-beam therapy, long-term follow-upPietro Valerio Foti, Antonio Longo, Michele Reibaldi, et al.
Autoimmunity Reviews|April 29, 2026
Dynamic profiling in inflammatory Bowel disease: A manifesto for personalized careGiuseppe Privitera, Mariangela Allocca, Luca Antonioli, et al.
Autoimmunity Reviews|June 4, 2026
Corrigendum to 'Dynamic profiling in inflammatory Bowel disease: A manifesto for personalized care' [Autoimmunity Reviews 25 (2026) 104068]Giuseppe Privitera, Mariangela Allocca, Luca Antonioli, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Journal of Crohn'S & Colitis|June 18, 2026
Virtual chromoendoscopy with linked color imaging versus dye-chromoendoscopy in the surveillance of patients with long-standing colonic inflammatory bowel diseaseRoberto Gabbiadini, Gianluca Franchellucci, Francesco Minini, et al.
Journal of Crohn'S & Colitis|December 27, 2025
Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC studyGiuseppe Privitera, Cristina Bezzio, Arianna Dal Buono, et al.
United European Gastroenterology Journal|November 9, 2019
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel diseaseLuisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, et al.
Neurogenetics|February 5, 2013
Natural history of neurofibromatosis type 2 with onset before the age of 1 yearMartino Ruggieri, Anna Lia Gabriele, Agata Polizzi, et al.
Cancers|February 5, 2021
Challenges in Crohn's Disease Management after Gastrointestinal Cancer DiagnosisClaudio Fiorillo, Carlo Alberto Schena, Giuseppe Quero, et al.
Expert Opinion on Biological Therapy|October 19, 2020
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patientsDaniela Pugliese, Luisa Guidi, Giuseppe Privitera, et al.
Journal of Crohn'S & Colitis|July 17, 2020
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel DiseaseGiuseppe Privitera, Sara Onali, Daniela Pugliese, et al.
La Radiologia Medica|October 19, 2016
Uveal melanoma: quantitative evaluation of diffusion-weighted MR imaging in the response assessment after proton-beam therapy, long-term follow-upPietro Valerio Foti, Antonio Longo, Michele Reibaldi, et al.
Autoimmunity Reviews|April 29, 2026
Dynamic profiling in inflammatory Bowel disease: A manifesto for personalized careGiuseppe Privitera, Mariangela Allocca, Luca Antonioli, et al.
Autoimmunity Reviews|June 4, 2026
Corrigendum to 'Dynamic profiling in inflammatory Bowel disease: A manifesto for personalized care' [Autoimmunity Reviews 25 (2026) 104068]Giuseppe Privitera, Mariangela Allocca, Luca Antonioli, et al.
Pageof 10